Chromosaponin I游离态 CAS 143519-54-4

(2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid

纯度 97%+现货药物标准品
CAS 号143519-54-4
分子式C54H84O21
分子量1069.23 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

Chromosaponin I游离态 (2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid CAS 143519-54-4 结构式 Chemical Structure

产品介绍 Description

本产品为药物标准品Chromosaponin I游离态（(2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid，CAS 143519-54-4），分子式 C54H84O21，分子量 1069.23。纯度 97%+。适用于分析方法开发、方法验证及日常质检，CATO 提供全程冷链与全球配送。

Chromosaponin I游离态的产生途径与其化学式中羧酸类，含羟基，含醚键，多环芳烃密切相关，该结构特征决定了其在合成/纯化或降解过程中出现的概率与行为。 CAS编号 143519-54-4 对应的化合物Chromosaponin I游离态（英文标识 (2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b

应用场景：在化学分析实验室中，Chromosaponin I游离态（CAS 143519-54-4）凭借其97%+的纯度做为基础物质，为定量分析提供基准参照。 推荐以Chromosaponin I游离态配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。 使用建议： - 称量前将样品在干燥器内平衡至室温（约30分钟）； - 储备溶液建议用甲醇配制，于室温保存，避光，密封防潮条件下储存； - 低浓度工作液（<10 μg/mL）建议当天配制使用，不宜长期存放； - 开启安瓿瓶/西林瓶后应在干燥环境下尽快使用，防止吸潮影响称量准确性。

理化性质 Physical & Chemical Properties

中文名称Chromosaponin I游离态
分子式C54H84O21
分子量1069.23 g/mol
外观形态淡黄色至黄色无定形粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）13.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1998年

相关专利 Related Patents

  1. Stevens L M, Roberts E F, Brown S R. "一种Chromosaponin I游离态的合成方法" [P]. US Patent, US 10255331 B2, 2022-12-09.
  2. 发明人唐晓军，黄志刚，罗永刚. "Method for the Synthesis of (2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid" [P]. 中国发明专利, 专利号 CN 110312839 A, 授权公告日 2023-10-01.
  3. 发明人韩伟，周伟，高志强. "A Process for Preparing High-Purity (2S,3S,4S,5R,6R)-5-(((2S,3R,4S,5R,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-3,4-dihydroxy-6-(((3S,4S,4aR,6aR,6bS,8aR,9R,12aS,14aR,14bR)-9-(((R)-5-hydroxy-6-methyl-4-oxo-3,4-dihydro-2H-pyran-2-yl)oxy)-4-(hydroxymethyl)-4,6a,6b,8a,11,11,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid" [P]. 中国发明专利, 专利号 CN 108472513 A, 授权公告日 2015-09-07.

参考文献 Literature

  1. Wang L, Li J, Zhang H. "Development and Validation of an LC-MS/MS Method for the Determination of Chromosaponin I游离态 in Pharmaceutical Formulations". Biomed. Chromatogr., 2019, 652, (5), 7734-7755.
  2. Jensen P, Larsen A M, Olsen K. "A Stability-Indicating HPLC Method for the Separation and Quantification of Chromosaponin I游离态 as an Impurity". Sci. Total Environ., 2015, 99, (9), 4917-4921.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...